Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Chin-Hsien Lin 4 Articles
Historical and More Common Nongenetic Movement Disorders From Asia
Norlinah Mohamed Ibrahim, Priya Jagota, Pramod Kumar Pal, Roongroj Bhidayasiri, Shen-Yang Lim, Yoshikazu Ugawa, Zakiyah Aldaajani, Beomseok Jeon, Shinsuke Fujioka, Jee-Young Lee, Prashanth Lingappa Kukkle, Huifang Shang, Onanong Phokaewvarangkul, Cid Diesta, Cholpon Shambetova, Chin-Hsien Lin
J Mov Disord. 2023;16(3):248-260.   Published online June 9, 2023
DOI: https://doi.org/10.14802/jmd.22224
  • 2,311 View
  • 129 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary Material
Nongenetic movement disorders are common throughout the world. The movement disorders encountered may vary depending on the prevalence of certain disorders across various geographical regions. In this paper, we review historical and more common nongenetic movement disorders in Asia. The underlying causes of these movement disorders are diverse and include, among others, nutritional deficiencies, toxic and metabolic causes, and cultural Latah syndrome, contributed by geographical, economic, and cultural differences across Asia. The industrial revolution in Japan and Korea has led to diseases related to environmental toxin poisoning, such as Minamata disease and β-fluoroethyl acetate-associated cerebellar degeneration, respectively, while religious dietary restriction in the Indian subcontinent has led to infantile tremor syndrome related to vitamin B12 deficiency. In this review, we identify the salient features and key contributing factors in the development of these disorders.

Citations

Citations to this article as recorded by  
  • Diabetic striatopathy and other acute onset de novo movement disorders in hyperglycemia
    Subhankar Chatterjee, Ritwik Ghosh, Payel Biswas, Shambaditya Das, Samya Sengupta, Souvik Dubey, Biman Kanti Ray, Alak Pandit, Julián Benito-León, Rana Bhattacharjee
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(3): 102997.     CrossRef
Nine Hereditary Movement Disorders First Described in Asia: Their History and Evolution
Priya Jagota, Yoshikazu Ugawa, Zakiyah Aldaajani, Norlinah Mohamed Ibrahim, Hiroyuki Ishiura, Yoshiko Nomura, Shoji Tsuji, Cid Diesta, Nobutaka Hattori, Osamu Onodera, Saeed Bohlega, Amir Al-Din, Shen-Yang Lim, Jee-Young Lee, Beomseok Jeon, Pramod Kumar Pal, Huifang Shang, Shinsuke Fujioka, Prashanth Lingappa Kukkle, Onanong Phokaewvarangkul, Chin-Hsien Lin, Cholpon Shambetova, Roongroj Bhidayasiri
J Mov Disord. 2023;16(3):231-247.   Published online June 13, 2023
DOI: https://doi.org/10.14802/jmd.23065
  • 3,282 View
  • 239 Download
AbstractAbstract PDFSupplementary Material
Clinical case studies and reporting are important to the discovery of new disorders and the advancement of medical sciences. Both clinicians and basic scientists play equally important roles leading to treatment discoveries for both cures and symptoms. In the field of movement disorders, exceptional observation of patients from clinicians is imperative, not just for phenomenology but also for the variable occurrences of these disorders, along with other signs and symptoms, throughout the day and the disease course. The Movement Disorders in Asia Task Force (TF) was formed to help enhance and promote collaboration and research on movement disorders within the region. As a start, the TF has reviewed the original studies of the movement disorders that were preliminarily described in the region. These include nine disorders that were first described in Asia: Segawa disease, PARK-Parkin, X-linked dystonia-parkinsonism, dentatorubral-pallidoluysian atrophy, Woodhouse-Sakati syndrome, benign adult familial myoclonic epilepsy, Kufor-Rakeb disease, tremulous dystonia associated with mutation of the calmodulin-binding transcription activator 2 gene, and paroxysmal kinesigenic dyskinesia. We hope that the information provided will honor the original researchers and help us learn and understand how earlier neurologists and basic scientists together discovered new disorders and made advances in the field, which impact us all to this day.
Clinical Characteristics, Genetic Features, and Long-Term Outcome of Wilson’s Disease in a Taiwanese Population: An 11-Year Follow-Up Study
Sung-Pin Fan, Yih-Chih Kuo, Ni-Chung Lee, Yin-Hsiu Chien, Wuh-Liang Hwu, Yu-Hsuan Huang, Han-I Lin, Tai-Chung Tseng, Tung-Hung Su, Shiou-Ru Tzeng, Chien-Ting Hsu, Huey-Ling Chen, Chin-Hsien Lin, Yen-Hsuan Ni
J Mov Disord. 2023;16(2):168-179.   Published online March 6, 2023
DOI: https://doi.org/10.14802/jmd.22161
  • 2,573 View
  • 132 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFSupplementary Material
Objective
aaWilson’s disease (WD) is a rare genetic disorder of copper metabolism, and longitudinal follow-up studies are limited. We performed a retrospective analysis to determine the clinical characteristics and long-term outcomes in a large WD cohort.
Methods
aaMedical records of WD patients diagnosed from 2006–2021 at National Taiwan University Hospital were retrospectively evaluated for clinical presentations, neuroimages, genetic information, and follow-up outcomes.
Results
aaThe present study enrolled 123 WD patients (mean follow-up: 11.12 ± 7.41 years), including 74 patients (60.2%) with hepatic features and 49 patients (39.8%) with predominantly neuropsychiatric symptoms. Compared to the hepatic group, the neuropsychiatric group exhibited more Kayser-Fleischer rings (77.6% vs. 41.9%, p < 0.01), lower serum ceruloplasmin levels (4.9 ± 3.9 vs. 6.3 ± 3.9 mg/dL, p < 0.01), smaller total brain and subcortical gray matter volumes (p < 0.0001), and worse functional outcomes during follow-up (p = 0.0003). Among patients with available DNA samples (n = 59), the most common mutations were p.R778L (allelic frequency of 22.03%) followed by p.P992L (11.86%) and p.T935M (9.32%). Patients with at least one allele of p.R778L had a younger onset age (p = 0.04), lower ceruloplasmin levels (p < 0.01), lower serum copper levels (p = 0.03), higher percentage of the hepatic form (p = 0.03), and a better functional outcome during follow-up (p = 0.0012) compared to patients with other genetic variations.
Conclusion
aaThe distinct clinical characteristics and long-term outcomes of patients in our cohort support the ethnic differences regarding the mutational spectrum and clinical presentations in WD.

Citations

Citations to this article as recorded by  
  • ATP7B Gene Variant Profile İdentified by NGS in Wilson’s Disease
    Orhan Gorukmez, Taner Özgür, Ozlem Gorukmez, Ali Topak
    Fetal and Pediatric Pathology.2023; 42(6): 891.     CrossRef
Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease
Han-Lin Chiang, Chin-Hsien Lin
J Mov Disord. 2019;12(2):67-83.   Published online May 30, 2019
DOI: https://doi.org/10.14802/jmd.18067
  • 16,135 View
  • 751 Download
  • 64 Web of Science
  • 63 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is a common neurodegenerative disorder arising from an interplay between genetic and environmental risk factors. Studies have suggested that the pathological hallmarks of intraneuronal α-synuclein aggregations may start from the olfactory bulb and the enteric nervous system of the gut and later propagate to the brain via the olfactory tract and the vagus nerve. This hypothesis correlates well with clinical symptoms, such as constipation, that may develop up to 20 years before the onset of PD motor symptoms. Recent interest in the gut–brain axis has led to vigorous research into the gastrointestinal pathology and gut microbiota changes in patients with PD. In this review, we provide current clinical and pathological evidence of gut involvement in PD by summarizing the changes in gut microbiota composition and gut inflammation associated with its pathogenesis.

Citations

Citations to this article as recorded by  
  • Buty and the beast: the complex role of butyrate in Parkinson’s disease
    Joshua D. Elford, Nanette Becht, Johan Garssen, Aletta D. Kraneveld, Paula Perez-Pardo
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Adipose tissue, systematic inflammation, and neurodegenerative diseases
    AnaPaula de A. Boleti, PedroHenrique de O. Cardoso, BrenoEmanuel F. Frihling, PatríciaSouza e Silva, LuizFilipe R. N. de Moraes, Ludovico Migliolo
    Neural Regeneration Research.2023; 18(1): 38.     CrossRef
  • Parkinson's Disease: A Multisystem Disorder
    Helena Nunes Costa, Ana Raquel Esteves, Nuno Empadinhas, Sandra Morais Cardoso
    Neuroscience Bulletin.2023; 39(1): 113.     CrossRef
  • Brain modulation by the gut microbiota: From disease to therapy
    Sarmistha Mitra, Raju Dash, Amena Al Nishan, Sarmin Ummey Habiba, Il Soo Moon
    Journal of Advanced Research.2023; 53: 153.     CrossRef
  • Plasma Metabolic Analysis Reveals the Dysregulation of Short-Chain Fatty Acid Metabolism in Parkinson’s Disease
    Ao Qi, Lulu Liu, Junjie Zhang, Simei Chen, Simin Xu, Yusen Chen, Lijiang Zhang, Chun Cai
    Molecular Neurobiology.2023; 60(5): 2619.     CrossRef
  • Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study
    Herbert L. DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L. Brown, Heather T. Essigmann, Ashley S. Alexander, Andrew W. DuPont, Tehseen Iqbal, Netanya S. Utay, Michael Newmark, Mya C. Schiess
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases
    Mohamed S. Attia, Ahmed Yahya, Nada Abdel Monaem, Shereen A. Sabry
    Saudi Pharmaceutical Journal.2023; 31(3): 417.     CrossRef
  • GSDMD in peripheral myeloid cells regulates microglial immune training and neuroinflammation in Parkinson's disease
    Bingwei Wang, Yan Ma, Sheng Li, Hang Yao, Mingna Gu, Ying Liu, You Xue, Jianhua Ding, Chunmei Ma, Shuo Yang, Gang Hu
    Acta Pharmaceutica Sinica B.2023; 13(6): 2663.     CrossRef
  • Gut-microbiome-brain axis: the crosstalk between the vagus nerve, alpha-synuclein and the brain in Parkinson’s disease
    Júlio César Claudino dos Santos, Leandro Freitas Oliveira, Felipe Micelli Noleto, Camilla Teixeira Pinheiro Gusmão, Gerly Anne de Castro Brito, Glauce Socorro de Barros Viana
    Neural Regeneration Research.2023; 18(12): 2611.     CrossRef
  • Beyond the Microbiota: Understanding the Role of the Enteric Nervous System in Parkinson’s Disease from Mice to Human
    Martina Montanari, Paola Imbriani, Paola Bonsi, Giuseppina Martella, Antonella Peppe
    Biomedicines.2023; 11(6): 1560.     CrossRef
  • Effects of gut microbiota on neurodegenerative diseases
    Saima Khatoon, Nida Kalam, Summya Rashid, Gulnaz Bano
    Frontiers in Aging Neuroscience.2023;[Epub]     CrossRef
  • From-Toilet-to-Freezer: A Review on Requirements for an Automatic Protocol to Collect and Store Human Fecal Samples for Research Purposes
    Frances Widjaja, Ivonne M. C. M. Rietjens
    Biomedicines.2023; 11(10): 2658.     CrossRef
  • Association between the risk and severity of Parkinson’s disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis
    Yuxin Quan, Jisen Xu, Qing Xu, Zhiqing Guo, Ruwei Ou, Huifang Shang, Qianqian Wei
    Frontiers in Aging Neuroscience.2023;[Epub]     CrossRef
  • Oral pathogens exacerbate Parkinson’s disease by promoting Th1 cell infiltration in mice
    Xue-Bing Bai, Shuo Xu, Lu-Jun Zhou, Xiao-Qian Meng, Yu-Lin Li, Yan-Lin Chen, Yi-Han Jiang, Wen-Zhen Lin, Bo-Yan Chen, Lin-Juan Du, Guo-Cai Tian, Yan Liu, Sheng-Zhong Duan, Ya-Qin Zhu
    Microbiome.2023;[Epub]     CrossRef
  • The intestinal luminal sources of α-synuclein: a gastroenterologist perspective
    Aaron Lerner
    Nutrition Reviews.2022; 80(2): 282.     CrossRef
  • Mild Chronic Colitis Triggers Parkinsonism in LRRK2 Mutant Mice Through Activating TNF‐α Pathway
    Chin‐Hsien Lin, Han‐Yi Lin, En‐Pong Ho, Yi‐Ci Ke, Mei‐Fang Cheng, Chyng‐Yann Shiue, Chi‐Han Wu, Peng‐Hsiang Liao, Angela Yu‐Huey Hsu, Li‐An Chu, Ya‐Ding Liu, Ya‐Hui Lin, Yi‐Cheng Tai, Chia‐Tung Shun, Han‐Mo Chiu, Ming‐Shiang Wu
    Movement Disorders.2022; 37(4): 745.     CrossRef
  • Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson’s disease
    Ehraz Anis, Aoji Xie, Lena Brundin, Patrik Brundin
    Trends in Endocrinology & Metabolism.2022; 33(2): 147.     CrossRef
  • Animal models of brain-first and body-first Parkinson's disease
    Nathalie Van Den Berge, Ayse Ulusoy
    Neurobiology of Disease.2022; 163: 105599.     CrossRef
  • Microbiome Changes in Humans with Parkinson’s Disease after Photobiomodulation Therapy: A Retrospective Study
    Brian Bicknell, Ann Liebert, Craig S. McLachlan, Hosen Kiat
    Journal of Personalized Medicine.2022; 12(1): 49.     CrossRef
  • Passive Immunization in Alpha-Synuclein Preclinical Animal Models
    Jonas Folke, Nelson Ferreira, Tomasz Brudek, Per Borghammer, Nathalie Van Den Berge
    Biomolecules.2022; 12(2): 168.     CrossRef
  • Dietary Succinoglycan Riclin Improves Glycemia Control in Mice with Type 2 Diabetes
    Zhao Ding, Yang Zhao, Junhao Liu, Wenhao Ge, Xi Xu, Shiming Wang, Jianfa Zhang
    Journal of Agricultural and Food Chemistry.2022; 70(6): 1819.     CrossRef
  • Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
    Sevag Hamamah, Armin Aghazarian, Anthony Nazaryan, Andras Hajnal, Mihai Covasa
    Biomedicines.2022; 10(2): 436.     CrossRef
  • Distribution of α-Synuclein Aggregation in the Peripheral Tissues
    Yan-yan Li, Tian-tian Zhou, Yi Zhang, Nai-Hong Chen, Yu-He Yuan
    Neurochemical Research.2022; 47(12): 3627.     CrossRef
  • Effects of Subdiaphragmatic Vagotomy in the MPTP-induced Neurotoxicity in the Striatum and Colon of Mice
    Jiajing Shan, Youge Qu, Jiancheng Zhang, Li Ma, Kenji Hashimoto
    Clinical Psychopharmacology and Neuroscience.2022; 20(2): 389.     CrossRef
  • Alpha-Synuclein Strain Variability in Body-First and Brain-First Synucleinopathies
    Mie Kristine Just, Hjalte Gram, Vasileios Theologidis, Poul Henning Jensen, K. Peter R. Nilsson, Mikael Lindgren, Karoline Knudsen, Per Borghammer, Nathalie Van Den Berge
    Frontiers in Aging Neuroscience.2022;[Epub]     CrossRef
  • Urolithins: potential biomarkers of gut dysbiosis and disease stage in Parkinson's patients
    María Romo-Vaquero, Emiliano Fernández-Villalba, Ana-Luisa Gil-Martinez, Lorena Cuenca-Bermejo, Juan Carlos Espín, María Trinidad Herrero, María Victoria Selma
    Food & Function.2022; 13(11): 6306.     CrossRef
  • Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease
    Hiroshi Nishiwaki, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Takumi Yoshida, Hiroyuki Hanada, Ichiro Takeuchi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Opicapone, a Novel Catechol-O-methyl Transferase Inhibitor, for Treatment of Parkinson’s Disease “Off” Episodes
    Amnon A. Berger, Ariel Winnick, Jonathan Izygon, Binil M. Jacob, Jessica S. Kaye, Rachel J. Kaye, Elisa E. Neuchat, Adam M. Kaye, Edward S. Alpaugh, Elyse M. Cornett, Andrew H. Han, Alan D. Kaye
    Health Psychology Research.2022;[Epub]     CrossRef
  • The role of LRRK2 in the periphery: link with Parkinson's disease and inflammatory diseases
    George Tsafaras, Veerle Baekelandt
    Neurobiology of Disease.2022; 172: 105806.     CrossRef
  • What Is the Prognostic Significance of Rapid Eye Movement Sleep Without Atonia in a Polysomnogram?
    Frank Ralls, Lisa Cutchen, Madeleine M. Grigg-Damberger
    Journal of Clinical Neurophysiology.2022; 39(5): 346.     CrossRef
  • Lippia grata essential oil complexed with β-cyclodextrin ameliorates biochemical and behavioral deficits in an animal model of progressive parkinsonism
    Jose Ivo A. Beserra-Filho, Amanda Maria-Macêdo, Suellen Silva-Martins, Ana Cláudia Custódio-Silva, Beatriz Soares-Silva, Sara Pereira Silva, Rafael Herling Lambertucci, Adriano Antunes de Souza Araújo, Angélica Maria Lucchese, Lucindo J. Quintans-Júnior,
    Metabolic Brain Disease.2022; 37(7): 2331.     CrossRef
  • Oral and gut dysbiosis leads to functional alterations in Parkinson’s disease
    Sungyang Jo, Woorim Kang, Yun Su Hwang, Seung Hyun Lee, Kye Won Park, Mi Sun Kim, Hyunna Lee, Hyung Jeong Yoon, Yoo Kyoung Park, Mauricio Chalita, Je Hee Lee, Hojun Sung, Jae-Yun Lee, Jin-Woo Bae, Sun Ju Chung
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Deciphering Intertwined Molecular Pathways Underlying Metabolic Syndrome Leading to Parkinson’s Disease
    Ritu Soni, Jigna Shah
    ACS Chemical Neuroscience.2022; 13(15): 2240.     CrossRef
  • Therapeutic potential of short-chain fatty acid production by gut microbiota in neurodegenerative disorders
    Sarika Yadav, Ashish Dwivedi, Anurag Tripathi, Amit Kumar Tripathi
    Nutrition Research.2022; 106: 72.     CrossRef
  • Development of neurodegenerative disorders and the role of gut
    Woong-Woo Lee
    Journal of Geriatric Neurology.2022; 1(2): 53.     CrossRef
  • What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review
    Bruno Bonnechère, Najaf Amin, Cornelia van Duijn
    International Journal of Molecular Sciences.2022; 23(22): 13665.     CrossRef
  • Gut microbiota in dementia with Lewy bodies
    Hiroshi Nishiwaki, Jun Ueyama, Kenichi Kashihara, Mikako Ito, Tomonari Hamaguchi, Tetsuya Maeda, Yoshio Tsuboi, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
    npj Parkinson's Disease.2022;[Epub]     CrossRef
  • Gut dysbiosis in stroke and its implications on Alzheimer’s disease‐like cognitive dysfunction
    Justin Cho, You Jeong Park, Bella Gonzales‐Portillo, Madeline Saft, Blaise Cozene, Nadia Sadanandan, Cesar V. Borlongan
    CNS Neuroscience & Therapeutics.2021; 27(5): 505.     CrossRef
  • Plasma Lipopolysaccharide-Binding Protein Reflects Risk and Progression of Parkinson’s Disease
    Szu-Ju Chen, Yu-Chiao Chi, Chang-Han Ho, Wei-Shiung Yang, Chin-Hsien Lin
    Journal of Parkinson's Disease.2021; 11(3): 1129.     CrossRef
  • Parkinson's disease and the gut: Models of an emerging relationship
    Adam J. Bindas, Subhash Kulkarni, Ryan A. Koppes, Abigail N. Koppes
    Acta Biomaterialia.2021; 132: 325.     CrossRef
  • Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats
    Nathalie Van Den Berge, Nelson Ferreira, Trine Werenberg Mikkelsen, Aage Kristian Olsen Alstrup, Gültekin Tamgüney, Páll Karlsson, Astrid Juhl Terkelsen, Jens Randel Nyengaard, Poul Henning Jensen, Per Borghammer
    Brain.2021; 144(6): 1853.     CrossRef
  • Desulfovibrio Bacteria Are Associated With Parkinson’s Disease
    Kari E. Murros, Vy A. Huynh, Timo M. Takala, Per E. J. Saris
    Frontiers in Cellular and Infection Microbiology.2021;[Epub]     CrossRef
  • “Janus-Faced” α-Synuclein: Role in Parkinson’s Disease
    Bipul Ray, Arehally M. Mahalakshmi, Sunanda Tuladhar, Abid Bhat, Asha Srinivasan, Christophe Pellegrino, Anbarasu Kannan, Srinivasa Rao Bolla, Saravana Babu Chidambaram, Meena Kishore Sakharkar
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • Influence of probiotic bacteria on gut microbiota composition and gut wall function in an in-vitro model in patients with Parkinson's disease
    Jonas Ghyselinck, Lynn Verstrepen, Frédéric Moens, Pieter Van Den Abbeele, Arnout Bruggeman, Jawal Said, Barry Smith, Lynne Ann Barker, Caroline Jordan, Valentina Leta, K. Ray Chaudhuri, Abdul W. Basit, Simon Gaisford
    International Journal of Pharmaceutics: X.2021; 3: 100087.     CrossRef
  • The Role of The Gut Microbiome in Parkinson’s Disease
    Amy Gallop, James Weagley, Saif-ur-Rahman Paracha, George Grossberg
    Journal of Geriatric Psychiatry and Neurology.2021; 34(4): 253.     CrossRef
  • The Baseline Structure of the Enteric Nervous System and Its Role in Parkinson’s Disease
    Gianfranco Natale, Larisa Ryskalin, Gabriele Morucci, Gloria Lazzeri, Alessandro Frati, Francesco Fornai
    Life.2021; 11(8): 732.     CrossRef
  • Regulation of neurotoxicity in the striatum and colon of MPTP-induced Parkinson’s disease mice by gut microbiome
    Jiajing Shan, Youge Qu, Siming Wang, Yan Wei, Lijia Chang, Li Ma, Kenji Hashimoto
    Brain Research Bulletin.2021; 177: 103.     CrossRef
  • Cholecystectomy and subsequent risk of Parkinson’s disease: a nationwide retrospective cohort study
    Ryul Kim, Jee-Young Lee, Sanghyun Park, Kyungdo Han, Cheol Min Shin
    npj Parkinson's Disease.2021;[Epub]     CrossRef
  • Benefits of Helicobacter pylori Eradication on Extragastric Diseases
    Tae Jun Kim, Hyuk Lee
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2021; 21(4): 275.     CrossRef
  • Higher cerebrospinal fluid to plasma ratio of p-cresol sulfate and indoxyl sulfate in patients with Parkinson’s disease
    Bartłomiej Sankowski, Karolina Księżarczyk, Emilia Raćkowska, Stanisław Szlufik, Dariusz Koziorowski, Joanna Giebułtowicz
    Clinica Chimica Acta.2020; 501: 165.     CrossRef
  • The microbiome-gut-brain axis in acute and chronic brain diseases
    Corinne Benakis, Camille Martin-Gallausiaux, Jean-Pierre Trezzi, Philip Melton, Arthur Liesz, Paul Wilmes
    Current Opinion in Neurobiology.2020; 61: 1.     CrossRef
  • The progress of gut microbiome research related to brain disorders
    Sibo Zhu, Yanfeng Jiang, Kelin Xu, Mei Cui, Weimin Ye, Genming Zhao, Li Jin, Xingdong Chen
    Journal of Neuroinflammation.2020;[Epub]     CrossRef
  • Minireview on the Relations between Gut Microflora and Parkinson’s Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities
    Ovidiu-Dumitru Ilie, Alin Ciobica, Jack McKenna, Bogdan Doroftei, Ioannis Mavroudis, Tuane B. Sampaio
    Oxidative Medicine and Cellular Longevity.2020; 2020: 1.     CrossRef
  • Microbiota-gut-brain axis in health and disease: Is NLRP3 inflammasome at the crossroads of microbiota-gut-brain communications?
    Carolina Pellegrini, Luca Antonioli, Vincenzo Calderone, Rocchina Colucci, Matteo Fornai, Corrado Blandizzi
    Progress in Neurobiology.2020; 191: 101806.     CrossRef
  • Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease
    Hiroshi Nishiwaki, Mikako Ito, Tomohiro Ishida, Tomonari Hamaguchi, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno
    Movement Disorders.2020; 35(9): 1626.     CrossRef
  • In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
    Maria Fouka, Panagiota Mavroeidi, Grigoria Tsaka, Maria Xilouri
    Frontiers in Cell and Developmental Biology.2020;[Epub]     CrossRef
  • Role of Carbon Monoxide in Host–Gut Microbiome Communication
    Christopher P. Hopper, Ladie Kimberly De La Cruz, Kristin V. Lyles, Lauren K. Wareham, Jack A. Gilbert, Zehava Eichenbaum, Marcin Magierowski, Robert K. Poole, Jakob Wollborn, Binghe Wang
    Chemical Reviews.2020; 120(24): 13273.     CrossRef
  • Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
    Chrysoula Marogianni, Maria Sokratous, Efthimios Dardiotis, Georgios M. Hadjigeorgiou, Dimitrios Bogdanos, Georgia Xiromerisiou
    International Journal of Molecular Sciences.2020; 21(22): 8421.     CrossRef
  • Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease
    Tennekoon B. Karunaratne, Chijioke Okereke, Marissa Seamon, Sharad Purohit, Chandramohan Wakade, Amol Sharma
    Nutrients.2020; 13(1): 28.     CrossRef
  • Short-Chain Fatty Acid-Producing Gut Microbiota Is Decreased in Parkinson’s Disease but Not in Rapid-Eye-Movement Sleep Behavior Disorder
    Hiroshi Nishiwaki, Tomonari Hamaguchi, Mikako Ito, Tomohiro Ishida, Tetsuya Maeda, Kenichi Kashihara, Yoshio Tsuboi, Jun Ueyama, Teppei Shimamura, Hiroshi Mori, Ken Kurokawa, Masahisa Katsuno, Masaaki Hirayama, Kinji Ohno, Chaysavanh Manichanh
    mSystems.2020;[Epub]     CrossRef
  • The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge
    Sven C. D. van IJzendoorn, Pascal Derkinderen, Teus van Laar
    Journal of Parkinson's Disease.2019; 9(s2): S323.     CrossRef
  • Medical management, prevention and mitigation of environmental risks factors in Neurology
    J. Reis, G.C. Román, M. Giroud, V.S. Palmer, P.S. Spencer
    Revue Neurologique.2019; 175(10): 698.     CrossRef
  • Antibiotic-induced microbiome depletion protects against MPTP-induced dopaminergic neurotoxicity in the brain
    Yaoyu Pu, Lijia Chang, Youge Qu, Siming Wang, Kai Zhang, Kenji Hashimoto
    Aging.2019; 11(17): 6915.     CrossRef

JMD : Journal of Movement Disorders Twitter